- Home
- IMUX
IMUX
Immunic Inc.
as 02-21-2025 4:00pm EST
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 86.3M | IPO Year: | N/A |
| Target Price: | $12.67 | AVG Volume (30 days): | 781.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.92 - $2.11 | Next Earning Date: | 03-04-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Immunic Inc. News
IMUX Breaking Stock News: Dive into IMUX Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 hours ago
Immunic, Inc.'s (NASDAQ:IMUX) largest shareholders are retail investors who were rewarded as market cap surged US$24m last week
PR Newswire
2 days ago
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
PR Newswire
18 days ago
Immunic to Participate in Investor and Scientific Conferences in February
PR Newswire
a month ago
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
ACCESSWIRE
3 months ago
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
PR Newswire
3 months ago
Immunic, Inc. to Participate in Investor Conference in December
Simply Wall St.
3 months ago
Insider Buys Additional US$100k In Immunic Stock
TipRanks
3 months ago
Immunic announces publication of IMU-856 data
Compare IMUX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMUX Immunic Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.